Evidence map›Paper›PMID 34626356›Full record

ArticleCancer treatment and research2021

Current Management and New Developments in the Treatment of ALL.

Justin Darrah, Weili Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer treatment and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Justin DarrahDivision of Hematology and Cellular Therapy, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA. justin.darrah@cshs.org.
Weili SunCity of Hope National Medical Center, Duarte, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the recent advent of newer targeted therapies, including blinatumomab, inotuzumab ozogamicin, tyrosine kinase inhibitors (TKIs), and CAR T cells, treatment approaches to newly diagnosed as well as relapsed/refractory acute lymphoblastic leukemia (ALL) have changed. This chapter summarizes the newest treatment approaches in newly diagnosed T-cell and B-cell ALL, as well as the use of novel therapies for relapsed and refractory ALL.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansInotuzumab OzogamicinInotuzumab OzogamicinAcute lymphoblastic leukemiaAdolescents and young adults (AYA)B CellPhiladelphia chromosomeRelapsedT Cell

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.